Clinical trial · Interventional
Luspatercept in Metastatic AGCT of the Ovary
Luspatercept in Metastatic Adult Granulosa Cell Tumor (AGCT) of the Ovary
NCT06254781CI-TRIAL-00073925completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a single participant study of luspatercept for the treatment of a patient with dult granulosa cell tumor (AGCT) of the ovary.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adult Granulosa Cell Tumor of the Ovary | Ovarian Granulosa Cell Tumor | ALIAS | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Luspatercept | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Luspatercept in metastatic AGCT of the ovary
- description
- Luspatercept, 1.0 mg/kg, subcutaneously, every three weeks
- interventionNames
- Drug: Luspatercept
Primary outcomes (3)
- measure
- Objective response
- timeFrame
- From baseline CT until disease progression or until the investigator deems that it is in the patient's best interest to stop study treatment, whichever came first, assessed up to 3 months.
- description
- By computed tomography (CT) scans
- measure
- Eastern Cooperative Oncology Group (ECOG) score
- timeFrame
- From baseline ECOG until disease progression or until the investigator deems that it is in the patient's best interest to stop study treatment, whichever came first, assessed up to 3 months.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * N/A Exclusion Criteria: * N/A This patient's case was recently discussed in the hospital expert molecular tumor board rounds consisting of representatives from specialist genomic profiling and gynecologic medical oncology departments. The discussion surrounded the best next therapeutic option in this rare cancer subtype without clear standard of care guidelines. The recommendation from this discussion was to investigate targets of the TGFβ pathway, such as luspatercept. Therefore, specific eligibility criteria aside from individual patient's medical history is not applicable.
References
Publications (0)
Data not yet available
No reference posted for this study.